{"result": {"id": "5efb6c44-27bd-4595-8be6-fd648781c0b8", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>JAMA<|>ORGANIZATION<|>Journal of the American Medical Association, which published the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>NATURE<|>ORGANIZATION<|>Scientific journal that published the study on in vivo CRISPR base editing of PCSK9\")\n##\n(\"entity\"<|>LANCET<|>ORGANIZATION<|>Medical journal that published the phase 3 study on microsomal triglyceride transfer protein inhibitor\")\n##\n(\"entity\"<|>NEW ENGLAND JOURNAL OF MEDICINE<|>ORGANIZATION<|>Medical journal that published studies on evinacumab and volanesorsen\")\n##\n(\"entity\"<|>AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY<|>ORGANIZATION<|>Journal that published the study on lipoprotein(a) therapeutics\")\n##\n(\"entity\"<|>NATURE REVIEWS CARDIOLOGY<|>ORGANIZATION<|>Journal that published the review on novel lipid-modulating therapies\")\n##\n(\"entity\"<|>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY<|>ORGANIZATION<|>Journal that published the phase 2b trial of MK-0616\")\n##\n(\"relationship\"<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>JAMA<|>The trial results were published in JAMA<|>9)\n##\n(\"relationship\"<|>MUSUNURU K<|>NATURE<|>Musunuru K's CRISPR study was published in Nature<|>9)\n##\n(\"relationship\"<|>CUCHEL M<|>LANCET<|>Cuchel M's phase 3 study was published in The Lancet<|>9)\n##\n(\"relationship\"<|>RAAL FJ<|>NEW ENGLAND JOURNAL OF MEDICINE<|>Raal FJ's study on evinacumab was published in NEJM<|>9)\n##\n(\"relationship\"<|>WITZTUM JL<|>NEW ENGLAND JOURNAL OF MEDICINE<|>Witztum JL's study on volanesorsen was published in NEJM<|>9)\n##\n(\"relationship\"<|>KAUR G<|>AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY<|>Kaur G's study on lipoprotein(a) was published in AJPC<|>9)\n##\n(\"relationship\"<|>BRANDTS J<|>NATURE REVIEWS CARDIOLOGY<|>Brandts J's review was published in Nature Reviews Cardiology<|>9)\n##\n(\"relationship\"<|>BALLANTYNE CM<|>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY<|>Ballantyne CM's trial was published in JACC<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166561, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 614, "prompt_tokens": 4974, "total_tokens": 5588, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2880}, "prompt_cache_hit_tokens": 2880, "prompt_cache_miss_tokens": 2094}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: J]. Atherosclerosis,  2021, 325:99?109. DOI: 10.1016/j.atherosclerosis.2021.03.039.\n[60]      Goldberg AC, Leiter LA, Stroes E, et al. Effect of bempedoic acid vs  placebo  added to  maximally tolerated  statins  on low?density  lipoprotein  cholesterol  in  patients  at  high risk   for    cardiovascular   disease:   the    CLEAR    Wisdom Randomized    Clinical    Trial [J].    JAMA,    2019,     322 (18): 1780?1788. DOI: 10.1001/jama.2019.16585.\n[61]      Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects  of the  CETP  inhibitor  obicetrapib  in  combination with high?intensity statins: a randomized phase 2 trial[J]. Nat    Med,     2022,    28 (8):    1672?1678.    DOI:     10.1038/ s41591?022?01936?7.\n[62]       Cuchel  M,  Meagher  EA,  du  Toit  Theron  H,  et al.  Efficacy and  safety  of  a  microsomal  triglyceride  transfer  protein inhibitor      in      patients      with      homozygous      familial hypercholesterolaemia: a single?arm, open?label, phase  3 study[J].  Lancet,  2013,  381 (9860): 40?46.  DOI:  10.1016/ S0140?6736 (12)61731?0.\n[63]       Ballantyne   CM,    Banka   P,    Mendez   G,    et al.    Phase   2b randomized trial of the oral PCSK9 inhibitor MK?0616 [J]. J Am Coll Cardiol, 2023, 81 (16):1553?1564. DOI: 10.1016/ j.jacc.2023.02.018.\n[64]      Raal  FJ,  Rosenson  RS, Reeskamp LF, et al.  Evinacumab for homozygous  familial  hypercholesterolemia[J].   N   Engl  J Med,       2020,       383 (8):       711?720.       DOI:       10.1056/ NEJMoa2004215.\n[65]      Witztum  JL,  Gaudet  D,  Freedman  SD,  et al.  Volanesorsen and    triglyceride    levels    in     familial    chylomicronemia syndrome[J].  N  Engl  J  Med,  2019,  381 (6): 531?542.  DOI: 10. 1056/NEJMoa1715944.\n[66]      Kaur G, Abdelrahman K, Berman AN, et al. Lipoprotein(a): emerging insights and therapeutics[J]. Am J Prev Cardiol, 2024, 18:100641. DOI: 10.1016/j.ajpc.2024.100641.\n[67]      Brandts   J,   Ray   KK.   Novel   and   future   lipid?modulating therapies for the prevention of cardiovascular disease[J]. Nat  Rev  Cardiol,  2023,  20 (9): 600?616.  DOI:   10.1038/ s41569?023?00860?8.\n[68]       Musunuru  K,  Chadwick  AC,  Mizoguchi  T,  et al.   In  vivo CRISPR base editing of PCSK9 durably lowers cholesterol in  primates[J].   Nature,  2021,  593 (7859): 429?434.  DOI: 10.1038/s41586?021?03534?y.\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>EVENT<|>A clinical trial investigating the effect of bempedoic acid vs placebo on LDL cholesterol in high-risk cardiovascular patients\")\n##\n(\"entity\"<|>GOLDBERG AC<|>PERSON<|>Researcher involved in the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>LEITER LA<|>PERSON<|>Researcher involved in the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>STROES E<|>PERSON<|>Researcher involved in the CLEAR Wisdom Randomized Clinical Trial\")\n##\n(\"entity\"<|>NICHOLLS SJ<|>PERSON<|>Researcher involved in a phase 2 trial of CETP inhibitor obicetrapib\")\n##\n(\"entity\"<|>DITMARSCH M<|>PERSON<|>Researcher involved in a phase 2 trial of CETP inhibitor obicetrapib\")\n##\n(\"entity\"<|>KASTELEIN JJ<|>PERSON<|>Researcher involved in a phase 2 trial of CETP inhibitor obicetrapib\")\n##\n(\"entity\"<|>CUCHEL M<|>PERSON<|>Researcher involved in a phase 3 study of a microsomal triglyceride transfer protein inhibitor\")\n##\n(\"entity\"<|>MEAGHER EA<|>PERSON<|>Researcher involved in a phase 3 study of a microsomal triglyceride transfer protein inhibitor\")\n##\n(\"entity\"<|>DU TOIT THERON H<|>PERSON<|>Researcher involved in a phase 3 study of a microsomal triglyceride transfer protein inhibitor\")\n##\n(\"entity\"<|>BALLANTYNE CM<|>PERSON<|>Researcher involved in a phase 2b trial of the oral PCSK9 inhibitor MK-0616\")\n##\n(\"entity\"<|>BANKA P<|>PERSON<|>Researcher involved in a phase 2b trial of the oral PCSK9 inhibitor MK-0616\")\n##\n(\"entity\"<|>MENDEZ G<|>PERSON<|>Researcher involved in a phase 2b trial of the oral PCSK9 inhibitor MK-0616\")\n##\n(\"entity\"<|>RAAL FJ<|>PERSON<|>Researcher involved in a study on evinacumab for homozygous familial hypercholesterolemia\")\n##\n(\"entity\"<|>ROSENSON RS<|>PERSON<|>Researcher involved in a study on evinacumab for homozygous familial hypercholesterolemia\")\n##\n(\"entity\"<|>REESKAMP LF<|>PERSON<|>Researcher involved in a study on evinacumab for homozygous familial hypercholesterolemia\")\n##\n(\"entity\"<|>WITZTUM JL<|>PERSON<|>Researcher involved in a study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome\")\n##\n(\"entity\"<|>GAUDET D<|>PERSON<|>Researcher involved in a study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome\")\n##\n(\"entity\"<|>FREEDMAN SD<|>PERSON<|>Researcher involved in a study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome\")\n##\n(\"entity\"<|>KAUR G<|>PERSON<|>Researcher involved in a study on lipoprotein(a) and emerging therapeutics\")\n##\n(\"entity\"<|>ABDELRAHMAN K<|>PERSON<|>Researcher involved in a study on lipoprotein(a) and emerging therapeutics\")\n##\n(\"entity\"<|>BERMAN AN<|>PERSON<|>Researcher involved in a study on lipoprotein(a) and emerging therapeutics\")\n##\n(\"entity\"<|>BRANDTS J<|>PERSON<|>Researcher involved in a study on novel lipid-modulating therapies for cardiovascular disease prevention\")\n##\n(\"entity\"<|>RAY KK<|>PERSON<|>Researcher involved in a study on novel lipid-modulating therapies for cardiovascular disease prevention\")\n##\n(\"entity\"<|>MUSUNURU K<|>PERSON<|>Researcher involved in a study on in vivo CRISPR base editing of PCSK9 to lower cholesterol\")\n##\n(\"entity\"<|>CHADWICK AC<|>PERSON<|>Researcher involved in a study on in vivo CRISPR base editing of PCSK9 to lower cholesterol\")\n##\n(\"entity\"<|>MIZOGUCHI T<|>PERSON<|>Researcher involved in a study on in vivo CRISPR base editing of PCSK9 to lower cholesterol\")\n##\n(\"relationship\"<|>GOLDBERG AC<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>Goldberg AC was a researcher in the CLEAR Wisdom Randomized Clinical Trial<|>8)\n##\n(\"relationship\"<|>LEITER LA<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>Leiter LA was a researcher in the CLEAR Wisdom Randomized Clinical Trial<|>8)\n##\n(\"relationship\"<|>STROES E<|>CLEAR WISDOM RANDOMIZED CLINICAL TRIAL<|>Stroes E was a researcher in the CLEAR Wisdom Randomized Clinical Trial<|>8)\n##\n(\"relationship\"<|>NICHOLLS SJ<|>DITMARSCH M<|>Both researchers were involved in the same phase 2 trial of CETP inhibitor obicetrapib<|>7)\n##\n(\"relationship\"<|>NICHOLLS SJ<|>KASTELEIN JJ<|>Both researchers were involved in the same phase 2 trial of CETP inhibitor obicetrapib<|>7)\n##\n(\"relationship\"<|>DITMARSCH M<|>KASTELEIN JJ<|>Both researchers were involved in the same phase 2 trial of CETP inhibitor obicetrapib<|>7)\n##\n(\"relationship\"<|>CUCHEL M<|>MEAGHER EA<|>Both researchers were involved in the same phase 3 study of a microsomal triglyceride transfer protein inhibitor<|>7)\n##\n(\"relationship\"<|>CUCHEL M<|>DU TOIT THERON H<|>Both researchers were involved in the same phase 3 study of a microsomal triglyceride transfer protein inhibitor<|>7)\n##\n(\"relationship\"<|>MEAGHER EA<|>DU TOIT THERON H<|>Both researchers were involved in the same phase 3 study of a microsomal triglyceride transfer protein inhibitor<|>7)\n##\n(\"relationship\"<|>BALLANTYNE CM<|>BANKA P<|>Both researchers were involved in the same phase 2b trial of the oral PCSK9 inhibitor MK-0616<|>7)\n##\n(\"relationship\"<|>BALLANTYNE CM<|>MENDEZ G<|>Both researchers were involved in the same phase 2b trial of the oral PCSK9 inhibitor MK-0616<|>7)\n##\n(\"relationship\"<|>BANKA P<|>MENDEZ G<|>Both researchers were involved in the same phase 2b trial of the oral PCSK9 inhibitor MK-0616<|>7)\n##\n(\"relationship\"<|>RAAL FJ<|>ROSENSON RS<|>Both researchers were involved in the same study on evinacumab for homozygous familial hypercholesterolemia<|>7)\n##\n(\"relationship\"<|>RAAL FJ<|>REESKAMP LF<|>Both researchers were involved in the same study on evinacumab for homozygous familial hypercholesterolemia<|>7)\n##\n(\"relationship\"<|>ROSENSON RS<|>REESKAMP LF<|>Both researchers were involved in the same study on evinacumab for homozygous familial hypercholesterolemia<|>7)\n##\n(\"relationship\"<|>WITZTUM JL<|>GAUDET D<|>Both researchers were involved in the same study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome<|>7)\n##\n(\"relationship\"<|>WITZTUM JL<|>FREEDMAN SD<|>Both researchers were involved in the same study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome<|>7)\n##\n(\"relationship\"<|>GAUDET D<|>FREEDMAN SD<|>Both researchers were involved in the same study on volanesorsen and triglyceride levels in familial chylomicronemia syndrome<|>7)\n##\n(\"relationship\"<|>KAUR G<|>ABDELRAHMAN K<|>Both researchers were involved in the same study on lipoprotein(a) and emerging therapeutics<|>7)\n##\n(\"relationship\"<|>KAUR G<|>BERMAN AN<|>Both researchers were involved in the same study on lipoprotein(a) and emerging therapeutics<|>7)\n##\n(\"relationship\"<|>ABDELRAHMAN K<|>BERMAN AN<|>Both researchers were involved in the same study on lipoprotein(a) and emerging therapeutics<|>7)\n##\n(\"relationship\"<|>BRANDTS J<|>RAY KK<|>Both researchers were involved in the same study on novel lipid-modulating therapies for cardiovascular disease prevention<|>7)\n##\n(\"relationship\"<|>MUSUNURU K<|>CHADWICK AC<|>Both researchers were involved in the same study on in vivo CRISPR base editing of PCSK9 to lower cholesterol<|>7)\n##\n(\"relationship\"<|>MUSUNURU K<|>MIZOGUCHI T<|>Both researchers were involved in the same study on in vivo CRISPR base editing of PCSK9 to lower cholesterol<|>7)\n##\n(\"relationship\"<|>CHADWICK AC<|>MIZOGUCHI T<|>Both researchers were involved in the same study on in vivo CRISPR base editing of PCSK9 to lower cholesterol<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_72162e10c3910d0ca5c71e61558d0686427695907c2eae4d2515afd5202d3224_v2"}